Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-arm Study to De-escalate Adjuvant Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk of Metastasis

NCT05297617 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT05297617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05297617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-arm Study to De-escalate Adjuvant Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk of Metastasis
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Recruiting
Start date
October 12, 2022
Completion date
November 30, 2035
Enrollment
696 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer